New antidepressant offers substantial savings

Article

Patients in need of, or currently receiving, selective serotonin reuptake inhibitor (SSRI) therapy now have a branded formulation of paroxetine that is bioequivalent to paroxetine hydrochloride (Paxil, GlaxoSmithKline), yet available at a significant discount. The FDA recently approved paroxetine (Pexeva, Synthon Pharmaceuticals) mesylate for the treatment of major depressive disorder, obsessive/compulsive disorder (OCD), and panic disorder. The product is currently available in pharmacies.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

© 2025 MJH Life Sciences

All rights reserved.